Posts Tagged ‘Biopharma’
What are Allergan’s Next Steps?
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 081″] The near merger between Pfizer and Allergan clearly was financially motivated. But the deal promised to bring Pfizer’s firepower to ophthalmology. What does the annulment of the deal mean for our sector? Podcast Guest Brent Saunders Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests…
Read MoreKOL Corner: Can Complement Inhibitors Treat Macular Degeneration?
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 080″] The complement system is a promising target for drugs being developed to treat macular degeneration. But success has been elusive. A leading KOL and two CEOs explain what the future of the field may be. Podcast Transcript Tom Salemi: Hi, everyone, welcome back to the OIS Podcast. This is your…
Read MoreEye on Five – March Edition
Regeneron, Bayer Join to Develop Combined Therapy Regeneron Pharmaceuticals and Bayer announced an agreement to jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and aflibercept for the treatment of wet age-related macular degeneration or diabetic macular edema. Two separate Phase II clinical studies are evaluating the combination therapy as a co-formulated, single…
Read MoreVisionCare Battling Back Against Macular Degeneration
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 076″] CEO Wolfgang Tolle joined VisionCare last year to move the company into the commercial stage. Now with long-term data and reimbursement in place, the firm is making a strong commercial push. Transcript Tom Salemi: Hello, OIS Podcast listeners, this is Tom Salemi, your host. Thanks for joining us today on…
Read MoreHighlights from AGS: New Surgical Devices, Novel Therapeutics
This year’s American Glaucoma Society annual meeting feted novel medications designed to lower intraocular pressure (IOP) in patients with glaucoma. To date, available medications and surgery are designed to treat one of the primary risk factors – elevated IOP. But they are not designed to directly target the underlying degeneration that’s causing the vision loss.…
Read MoreHeier Talks Anti-Angiopoietin Programs, Clinical Trials & Red Sox
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 075″] Jeff Heier, MD, is the Director of the Vitreoretinal Service and the Director of Retina Research at Ophthalmic Consultants of Boston (OCB) gives an update from the Angiogenesis conference about the advancing anti-angiopoietin programs. Podcast Guest Jeffrey Heier, MD Jeffrey S. Heier, MD is the Director of the Vitreoretinal Service…
Read MoreKOL Corner: Alcon, Transcend & Glaucoma 360
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 074″] Glaucoma once might have been a boring or sleepy sub-specialty of ophthalmology, but recent technical advances and significant bets placed by large strategics including Alcon’s planned ac-quisition of Transcend has injected the sector with enthusiasm and energy. OIS Podcast, in our new KOL Corner features, talks with leading glaucoma specialists…
Read MoreApellis IPO Road Show Takes Different Route
Putting Brakes on IPO, Apellis Lines Up Private Funding As the stock market took its 2016 nosedive, geographic atrophy drug developer Apellis Pharmaceuticals joined the parade of biotech companies that put the brakes on planned public offerings and turned back to private equity for the capital to drive their development programs. Apellis filed last fall…
Read MoreAvalanche’s Post-AMD Pivot Takes Step Outside Ophthalmology
How far will Avalanche Biotechnologies Inc.’s pivot take it outside of ophthalmology? Following the release of disappointing topline results of its lead gene therapy candidate for age-related macular degeneration last June, Avalanche Biotechnologies has undertaken a series of significant pivots to right its ship. After releasing those results, the Menlo Park, CA, biotech company underwent…
Read MoreInotek’s Southwell & McVicar Have Designs on Treating Glaucoma
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 070″] Inotek CEO David Southwell and William K. McVicar PhD Executive Vice President, Chief Scientific Officer, share Inotek’s plan to bring to market a new first-line for glaucoma sufferers. Podcast Guest David P. Southwell Mr. Southwell has been President and CEO since August 2014, and led Inotek through its IPO and…
Read MoreOpthea Taking New Approach to Combat Wet AMD
Megan Baldwin, PhD, Managing Director and CEO of Opthea, gives an update on OPT-302, a soluble receptor consisting of the first three extracellular domains of human VEGFR-3 linked to the Fc region of hIgG1. Baldwin explains how OPT-302 potently and specifically blocks VEGF-C and VEGF-D from binding and activating VEGFR-2 and VEGFR-3, making it a…
Read MoreOcular Therapeutix Taking Aim at Allergy Market
Amar Sawhney, PhD, Chairman, Chairman, President & CEO of Ocular Therapeutics, touts the performance of Dextenza, the company’s anti-allergy medication. Instead of taking one drop a day, allergy sufferers just need one treatmet of Dextenza to survive a whole season. Speaking With: Amar Sawhney, PhD Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since…
Read More